Randomized trial · people

Cerebrolysin: no overall benefit in acute ischemic stroke at 90 days

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this large trial Cerebrolysin did not improve overall stroke recovery, and the possible benefit in severe strokes is a lead to test, not a settled result.

Kind
Randomized trial
Studied in
People
Number studied
1070
Published
2012
Journal
Stroke

What they tested

The team tested whether Cerebrolysin works and is safe in people with an acute ischemic stroke, a stroke caused by a blocked blood vessel in the brain.

How the study was done

A double-blind, placebo-controlled randomized trial in 1070 patients in Asia, started within 12 hours of stroke symptoms, comparing 30 mL Cerebrolysin with placebo (a saline drip), each given as a daily intravenous infusion for 10 days on top of 100 mg aspirin daily, with follow-up to 90 days. The main outcome combined three stroke scales: the modified Rankin Scale (disability), the Barthel Index (daily-living ability) and the NIH Stroke Scale (NIHSS, stroke severity).

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking cerebrolysin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

On the main combined outcome, Cerebrolysin and placebo did not differ significantly. In a post hoc look at patients with severe strokes (NIHSS above 12), results leaned toward Cerebrolysin on the NIHSS (OR 1.27, CI lower bound 0.97) and the modified Rankin Scale (OR 1.27, CI lower bound 0.90), though these were trends. In that same severe group, death by 90 days was 20.2% with placebo and 10.5% with Cerebrolysin (hazard ratio 1.9661, CI lower bound 1.0013).

What it doesn’t show

The main result was neutral, and the hint of benefit in severe strokes comes from a post hoc subgroup analysis, which can't confirm an effect on its own. The researchers said a further trial is needed to check it.

The paper

Heiss et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012.

The compound

More studies on Cerebrolysin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking cerebrolysin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo